FDA Removes Authorizations for Three Solvents Used in Food Color Additives

On November 10, 2026, FDA issued two final orders removing (1) the authorized use of methylene chloride as a diluent in color additive mixtures in inks for marking fruit and vegetables and (2) authorizations for methylene chloride, ethylene dichloride, and trichloroethylene as extraction solvents in the production of certain color additives.

The orders partially grant and partially deny petitions submitted by the Environmental Defense Fund (EDF) and other environmental and public health groups and the International Association of Color Manufacturers (IACM). Taken together, however, the orders accomplish all of the actions requested by the EDF petition.

The EDF petition sought removal of the authorizations based on evidence that the solvents induced cancer in laboratory animals. That evidence was sufficient for FDA to remove the use of methylene chloride in ink additives for marking fruit and vegetables. However, FDA determined that the same regulatory mechanism—the Delaney Clause—did not apply to the solvents’ use in the production of certain color additives, because those solvents are only present in those uses as an impurity.

FDA nevertheless removed those authorizations because IACM had separately identified the uses as abandoned in its petition.

The orders are effective January 11, 2027. Comments on the Federal Register notices are due December 12, 2026.

Can FDA revoke a color additive authorization if the additive is found to cause cancer?

Under § 721 of the Federal Food, Drug, and Cosmetic Act (FFDCA), FDA is authorized to regulate color additives used in food, drugs, cosmetics, and certain medical devices. Color additives generally cannot be used unless FDA has approved their use through regulation. The basis for an approval of a color additive is a reasonable certainty of no harm under its intended conditions of use. FDA considers exposure levels, cumulative effects, and relevant safety factors, including those associated with animal studies. Furthermore, new safety evidence may justify repealing an existing authorization if FDA can no longer conclude that the additive meets this standard.

§ 721 established the Delaney Clause, which prohibits approval of certain color additives found to cause cancer in humans or animals. Under §721(d), FDA may revoke a color additive authorization when new safety evidence establishes either FDA can no longer conclude there is reasonable certainty of no harm or the additive must be deemed unsafe under the Delaney Clause.

Does the Delaney Clause apply to carcinogenic impurities in color additives?

FDA found that ethylene dichloride, methylene chloride, and trichloroethylene induce cancer in animals. However, FDA interprets the Delaney Clause to apply to the color additive itself, rather than carcinogenic impurities or nonfunctional constituents. FDA determined that methylene chloride qualifies as a color additive when used as a diluent in inks for marking fruits and vegetables under 21 CFR § 73.1 and therefore revoked that authorization. By contrast, FDA determined that the three solvents are impurities rather than color additives under 21 CFR §§ 73.30, 73.345, and 73.615 and denied the remaining requests.

The affected authorizations concerned the production of annatto extract, paprika oleoresin, and turmeric oleoresin. Unlike the methylene chloride revocation, this action was based on abandonment of the authorized uses rather than the Delaney Clause.

What do FDA’s actions mean for color additive manufacturers?

FDA actions reflect two distinct grounds for removing color additive authorizations: carcinogenicity under the Delaney Clause and abandonment of previously authorized uses. Although EPA has separately restricted methylene chloride and trichloroethylene under the Toxic Substances Control Act (TSCA), EPA cannot regulate FFDCA uses under TSCA. (The Fifth Circuit has since vacated EPA’s TSCA regulation for methylene chloride.)

Manufacturers and suppliers of affected color additives should review their manufacturing processes and formulations to ensure compliance with the amended regulations. Because the extraction solvent uses were reportedly already abandoned, the immediate practical impact of those amendments may be limited. However, the revocation of methylene chloride’s authorization under the Delaney Clause demonstrates that FDA is required to remove an authorized color additive use based on evidence of carcinogenicity, regardless of whether the associated cancer risk is considered minimal.

Philip A. Moffat Quoted by Chemical Watch on Requested Changes to New Mexico PFAS Law

On November 11, 2026, Verdant Law attorney Philip A. Moffat was quoted in a Chemical Watch article titled “New Mexico Regulators Urge Legislature to Strengthen State’s PFAS Law.”

The article covers the New Mexico Environment Department’s (NMED’s) November 5 presentation to the joint Radioactive and Hazardous Materials Committee, which requested legislative intervention to strengthen the state’s PFAS Protection Act.

Mr. Moffat commented on NMED’s request for explicit fee authority in the context of ongoing state-level litigation challenging the Act’s implementing regulations. That lawsuit, which has been fully briefed, challenges the regulations’ PFAS labeling mandate and fee provisions.

A separate federal lawsuit has resulted in a preliminary injunction blocking the labeling mandate. That injunction has been appealed to the Tenth Circuit, with a ruling expected in fall or early winter 2027.

NMED’s Legislative Asks

In its presentation, NMED outlined four legislative changes it believes are necessary to strengthen the regulatory framework and address issues raised by the ongoing legal challenges and preliminary injunction:

  1. Require reporting for exempt products.
  2. Accelerate the phaseout schedule.
  3. Sunset exemptions.
  4. Explicitly authorize NMED to assess and collect fees.

New Mexico’s 2027 Legislative Session is scheduled to begin January 19. 2027.

The presentation is part of NMED’s response to House Joint Memorial 3, passed in February 2026, which directs NMED to make recommendations on whether to keep, modify, or eliminate the Act’s exemptions—including its exemption for fluoropolymers.

NMED’s report is due August 1, 2027. The Department is accepting public comments on the exemptions through the end of the year.

A PDF of the Chemical Watch article is available here, and a copy of the slides from NMED’s presentation is available here.

EPA Releases First Agency-Wide PFAS Technology Strategy

On October 26, 2026, EPA released its first-ever agency-wide PFAS Technology, Evaluation, Coordination, and Harmonization (PFAS TECH) strategy. The strategy aims to address PFAS contamination through technology development and collaboration with federal partners, states, local leaders, and the private sector.

“This new effort will help catapult technology innovation on PFAS while supporting practical tools, funding, and technical assistance to benefit communities addressing local PFAS challenges,” EPA said in a press release.

The strategy, which is largely a compilation of existing and planned projects, has three overarching goals:

  1. Powering innovation in research and development. EPA will facilitate public-private partnerships to promote analytical method development and emerging technologies to remove PFAS from drinking water. EPA offices will also coordinate on organomineral and anaerobic digestion techniques for PFAS destruction and evaluate supercritical water oxidation, a process that EPA reports destroyed more than 99.99% of PFAS in firefighting foam at industrial scale.
  2. Demonstrating What’s Possible through Pilot-Scale Initiatives. EPA highlights partnerships with about 40 drinking water utilities to identify optimal treatment methods. The strategy also notes potential pilot projects with the Department of War and Department of Energy on emerging destruction technologies and a future framework for managing soil containing low concentrations of PFAS.
  3. Translating Progress into Practical Actions. EPA plans to publicly release a searchable tool for identifying appropriate destruction and disposal methods, called the PFAS Break the Bond Navigator. The tool will be updated on a rolling basis as EPA evaluates these technologies.

The strategy indicates that new R&D funding for PFAS destruction is coming through EPA’s Science to Achieve Results (STAR) grant program and Small Business Innovation Research programs. It also points to infrastructure law money for PFAS treatment, especially for small and rural systems.

According to the strategy, National Program Offices and Regional Offices will advance these actions over the next two years. EPA encourages interested parties to get involved by contacting PFASTECH@epa.gov.

Senate Farm Bill Targets FIFRA Exemptions and EPA–USDA Coordination

A new farm bill introduced in the Senate proposes several regulatory changes under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). If enacted, the bill would exclude certain biostimulants from the definition of “plant regulator,” exempt certain plant-incorporated protectants from FIFRA requirements, extend the deadline for interim registration review decisions, and expand coordination between EPA and the U.S. Department of Agriculture (USDA).

The Agricultural Act of 2026, S. 5526, was reported to the Senate by Senate Agriculture Committee Chairman John Boozman (R-AR) on September 24, 2026, and placed on the Senate calendar. The committee had advanced the legislation on a party-line vote on September 16.

Similar reform measures were included in a House farm bill, which passed the House in April.

Product Exclusions and Exemptions

The Agricultural Act of 2026 would exclude certain plant biostimulants from regulation under FIFRA by excluding them from the definition of “plant regulator.”

“Plant biostimulant” would be defined as a substance that supports a plant’s natural nutrition processes independently of its nutrient content and thereby improves nutrient availability, uptake or use efficiency, tolerance to abiotic stress, or consequent growth, development, quality, or yield. The biostimulant exclusion would cover plant biostimulants that EPA determines have a low-risk profile and that are of biological origin or contain qualifying synthetic equivalents.

The legislation would also add exclusions from the definition of plant regulator for substances intended to be produced and used within a plant, qualifying plant biostimulants, and qualifying vitamin hormone products. In addition, it would define “nutritional chemical” and exclude plant biostimulants and nutritional chemicals from FIFRA’s definition of “nitrogen stabilizer.”

Exclusion from FIFRA’s definition of plant regulator means that a product would not be regulated as a pesticide solely on that basis. If the product does not otherwise qualify as a pesticide under FIFRA Section 2(u), it would generally not be subject to FIFRA’s pesticide registration, labeling, and related regulatory requirements.

Several of the proposed exclusions overlap with existing EPA regulations. Under 40 C.F.R. § 152.6(f) and (g), qualifying vitamin-hormone products, plant nutrients, inoculants, and soil amendments are already excluded. The proposed amendments would therefore provide express statutory treatment for certain products already excluded by regulation while potentially extending exclusions to additional qualifying products.

A related change would adopt a definition of plant-incorporated protectant (PIP) and exempt PIPs resulting from endogenous genetic material found within or that could arise from the plant’s gene pool from FIFRA’s requirements. The exemption would take effect after EPA issues guidance, due within one year after enactment, but EPA would retain authority to regulate a specific PIP by order. This, too, builds on EPA’s regulatory definition of PIP and existing exemptions for qualifying PIPs at 40 C.F.R. part 174, subpart B.

Registration Reviews

The bill would replace the existing 2022 deadline for completing initial registration reviews with a new deadline of October 1, 2031, for completing interim registration review decisions for affected pesticides. This change would give EPA additional time to issue interim decisions, rather than requiring completion of the full registration review process by the deadline.

Interim decisions noticed before that date, where EPA has not completed applicable ESA effects determinations or necessary consultation, would have to include measures to reduce potential effects on listed species and designated critical habitat where applicable. In developing those measures, EPA would be required to take into account input from USDA and other members of the FIFRA interagency working group.

Interagency Coordination

The bill would also expand coordination between EPA, USDA, and other federal agencies.

The legislation would establish additional interagency coordination requirements concerning pesticide decisions under the Endangered Species Act (ESA). Before adopting certain ESA-related policies, strategies, workplans, or pilot programs, EPA would be required to consult other agencies participating in the FIFRA interagency working group and publish their input. It would also change the working group’s progress reports from every 180 days for five years to annually, require them to be posted on EPA’s website, and require the group to consult industry and nongovernmental stakeholders at least once a year.

The legislation would also increase USDA’s involvement in EPA pesticide risk mitigation decisions. EPA would be required to develop certain risk mitigation measures in coordination with USDA and publish an economic analysis of their implementation costs. EPA would also have to coordinate with USDA so that it has agronomic data from USDA and industry, and information on available alternatives, for use in registration and review decisions. EPA would then have to explain publicly how it used that information, including its reasons for declining to use it. The bill would also require EPA to coordinate with the Departments of Agriculture, Interior, and Commerce concerning certain ESA-related measures.

In addition, the legislation would establish an Office of Biotechnology Policy to provide for the effective coordination of agricultural policies and activities within USDA related to biotechnology.

Potential Implications

If the Agricultural Act of 2026 is enacted, manufacturers of qualifying plant biostimulants could face fewer FIFRA obligations, which could affect product classification, registration, and labeling. Pesticide registrants could see more USDA input into EPA risk mitigation decisions, with more attention to implementation costs, agricultural uses, and alternatives. EPA would keep its authority to regulate products that do not qualify for the new exclusions or exemptions.

Trade Groups Seek to Expand California Recycling Lawsuit to Challenge Packaging EPR Program

Not long after securing a preliminary injunction against a California law restricting recyclability claims, a group of trade associations is asking a federal court for permission to expand its lawsuit to challenge the state’s extended producer responsibility (EPR) program for packaging.

In an October 8, 2026, motion, the plaintiffs seek leave to add nine claims challenging various provisions of the EPR law—SB 54—as unconstitutionally vague and in violation of the First Amendment, Due Process Clause, and Equal Protection Clause. They also seek to add two state officials as defendants.

The plaintiffs initiated their challenge against California’s “Truth in Recycling” law—SB 343—in March, and secured a preliminary injunction against its enforcement in July.

“The statutory schemes of SB 343 and SB 54 are tightly interwoven—implementation of one informs implementation of the other,” the plaintiffs argue. “By amending the First Amended Complaint, Plaintiffs can pursue more complete relief from laws that place unconstitutional burdens on the products their members sell and seek to continue selling.”

They add that the request is timely because CalRecycle did not promulgate SB 54’s implementing regulations until May, after the lawsuit had been filed.

At least two other lawsuits challenging the EPR program are already pending. One, brought by environmental groups, alleges that the implementing regulations are insufficiently protective of the environment. Another, filed by 17 states and a trade association, raises constitutional arguments against SB 54 similar to those the plaintiffs now seek to assert.

SB 343 Requirements and Injunction

The Truth in Recycling law restricts what products and packaging can carry recyclability claims or the chasing arrows symbol. Its central “60/60 requirement” mandates that the labeled item be collected for recycling in jurisdictions serving at least 60% of Californians and processed by facilities serving at least 60% of recycling programs statewide.

In granting the preliminary injunction, the Southern District of California agreed with the plaintiffs that several provisions of SB 343 were likely to be unconstitutionally vague. These included terms such as “routinely becomes feedstock,” “consistent with the . . . Basel Convention,” “ensure[s]” and “prevent[s] . . . recyclability,” and an unclear reference to industry guidance.

Although the court found that these provisions were severable, it concluded that the law as a whole should be enjoined on First Amendment grounds. The court determined that California had likely failed to demonstrate that SB 343 advanced its asserted interests in improving recycling rates and reducing consumer confusion.

The court reasoned that California had not shown that businesses would redesign their products to meet the law’s requirements rather than simply remove recyclability claims. It also preliminarily concluded that SB 343 would leave consumers with less information about recyclability than they had before.

Proposed New Claims Against SB 54

In seeking leave to amend their complaint, the plaintiffs emphasize the similarities between their existing challenge to SB 343 and their proposed claims against SB 54.

“As already raised in this case, SB 343 uses ambiguous provisions to define the word ‘recyclable,’ and SB 54 incorporates that definition wholesale,” they argue. They contend that other provisions of SB 54 use terminology similar to language the court preliminarily found unconstitutionally vague in SB 343. They also argue that SB 54 imposes commercial speech restrictions that “overlap with those raised” in their original complaint.

The plaintiffs further invoke the need for complete relief and logistical challenges as reason to address both statutes simultaneously, arguing that both laws require updating design, materials, and labels on products and packaging.

The proposed amended complaint would specifically challenge the following provisions of SB 54:

  • Requirements that products and packaging be “recyclable” as unconstitutionally vague;
  • Requirements that certain products and packaging be recycled at incrementally increasing rates as unconstitutionally vague;
  • The meaning of “covered material categories” as unconstitutionally vague;
  • Source reduction requirements based on what is “nonrecyclable” or “less likely to be recycled” as unconstitutionally vague;
  • Recycling target rates as unconstitutionally vague;
  • Provisions governing whether products and packaging are “recyclable” or recycled at a specific rate as depriving the plaintiffs of property without due process;
  • Restrictions on how fees may be communicated to consumers on receipts or invoices as violating the First Amendment;
  • Financial obligations imposed on producers as violating the Equal Protection Clause and Due Process Clause; and
  • Eco-modulated fees “set by a private entity without sufficient government review” as violating the Due Process Clause.

The case is Cal. League of Food Producers v. Bonta, No. 3:26-cv-1675 (S.D. Cal.), filed March 17, 2026.

The ongoing challenges to the EPR program are Nat. Res. Def. Council v. Dep’t of Res. Recycling & Recovery, No. CPF-26-519769 (Cal. Super. Ct. S.F. Cnty. 2026), and State v. Heller, No. 2:26-cv-02214 (E.D. Cal. 2026).

Senate Bill Targets Toxic Substances in Single-Use Beverage Bottles

On September 24, 2026, Senator Peter Welch (D-VT) introduced S. 5525, the Banning Toxics from Plastic Bottles Act of 2026. If enacted, the bill would prohibit retailers from selling or distributing certain single-use beverage containers based on their plastic composition, coloration, or toxic substance content, including PFAS.

Prohibition

Section 3 of the bill, titled “Elimination of toxic substances and other substances that prevent recyclability in beverage containers,” would prohibit retailers, beginning two years after enactment, from selling, offering for sale, or distributing any single-use beverage container that:

  1. Is composed wholly or partially of polyethylene terephthalate glycol (PETG);
  2. Is opaque or pigmented a color other than transparent blue or transparent green;
  3. Contains polyethylene glycol (PEG); or
  4. Contains a “toxic substance.”

The prohibition is not limited to substances that are intentionally added.

Definition of “Toxic Substance”

The bill defines a toxic substance as any substance, mixture, or compound that may cause personal injury or disease to humans through ingestion, inhalation, or absorption through any body surface, or that may adversely impact the environment. The substance must also satisfy at least one of the five conditions set forth in Section 2(9)(B):

  1. Federal Reporting Requirements: The substance is subject to reporting requirements under the Emergency Planning and Community Right-to-Know Act (EPCRA), the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), or Section 112(r) of the Clean Air Act (CAA).
  2. Health Hazards: Specified federal agencies—including EPA, OSHA, the CDC, and NIOSH—have established that the substance poses an acute or chronic health hazard, including developmental, reproductive, or endocrine effects.
  3. Latent Disease: EPA or NIOSH has recognized that the substance may increase the risk of developing a latent disease.
  4. Specified Chemicals and Classifications: The substance falls within certain chemical classes, including PFAS, orthophthalates, certain bisphenol compounds, halogenated or nanoscale flame retardants, UV-328, or chlorinated paraffins. This condition also includes substances designated under specified international conventions or carcinogenicity classifications.
  5. Other Identified Hazards: EPA determines that a federal, state, or international intergovernmental agency has identified the substance or chemical class as posing specified health or environmental hazards, including carcinogenicity, reproductive or developmental toxicity, persistence and bioaccumulation, or adverse impacts on air, soil, or water quality.

Notably, the bill does not define PFAS.

Penalties

Violations would be subject to fines of up to $50,000 per violation. Each product line of beverage containers would constitute a separate violation. Penalties collected under this provision would be deposited into a Local Clean Up of Plastics Fund, which would provide grants to local governments for solid waste and water system infrastructure improvements.

Status

The bill has been referred to the Senate Committee on Commerce, Science, and Transportation. Senator Welch introduced similar legislation last Congress, which did not advance out of committee.

Sens. Merkley (D-OR), Booker (D-NJ), Van Hollen (D-MD), and Sanders (I-VT) are original cosponsors.

New Mexico Appeals PFAS Labeling Injunction to the Tenth Circuit

New Mexico has appealed a preliminary injunction against the state’s far-reaching PFAS labeling requirement to the Tenth Circuit.

The notice of appeal, filed October 16, 2026, concerns the portions of the district court’s order “holding that New Mexico’s PFAS label is unlikely to pass rational basis scrutiny under Zauderer v. Off. of Disciplinary Counsel, 471 U.S. 626 (1985).”

The District of New Mexico granted the preliminary injunction on September 21, 2026. Although the court preliminarily determined that the label was purely factual and uncontroversial under Zauderer, the court concluded that there was likely no reasonable connection between the labeling requirement and New Mexico’s asserted interests.

This conclusion rested on New Mexico’s characterization of the label as a consumer awareness disclosure rather than a warning. Specifically, the court questioned how the label furthers consumer awareness if it does not convey information about how PFAS may affect health or the environment.

“In characterizing the required label as a ‘consumer awareness label,’ and not a ‘warning label,’ Defendants destroy the connection between the purpose of the required disclosure – to promote consumer and environmental health – and the means employed to realize that purpose, which in other instances is achieved with a warning,” the order states.

If the preliminary injunction is lifted, the labeling requirement will take effect January 1, 2027, for all consumer products containing intentionally added PFAS except used products, pesticides, veterinary products, and medical devices and drugs.

In addition to the federal lawsuit, a state-court challenge to the rule is also ongoing.

What New Mexico May Argue on Appeal

A filing New Mexico submitted shortly after the injunction was granted may signal its appellate arguments.

On September 25, 2026, the state filed a submission in support of its motion to dismiss, in which it “respectfully ask[s] the Court to reconsider its reasoning” on whether the label is a reasonable fit. The state argues that the inquiry “does not hinge solely on what the label itself contains,” but instead “looks more broadly at what the label does.” This can be satisfied by common sense and logic, the filing contends.

According to the state, the label meets this standard because it allows consumers to avoid products containing PFAS, which “inherently furthers both the State’s public health and environmental protection interests.” In support, New Mexico points to record evidence that consumers are willing to pay more for PFAS-free products.

The state also argues that, under the district court’s reasoning, no ingredient disclosure could ever survive scrutiny without an accompanying warning. “This cannot be right,” the filing states, citing cases upholding labels for calorie counts and genetically engineered ingredients that did not include clarifying language about the underlying interest.

The case is Am. Chemistry Council v. Kenney, No. 1:26-cv-02130 (D.N.M.), filed July 1, 2026.

Update (October 21, 2026)

On October 20, 2026, the appeal was docketed as No. 26-2184.

Lawmakers Ask GAO to Review EPA’s Microplastics Research and Regulatory Efforts

Following EPA’s decision not to list microplastics in the proposed Sixth Unregulated Contaminant Monitoring Rule (UCMR 6), two dozen Democratic lawmakers are asking the Government Accountability Office (GAO) to review the Agency’s efforts to assess human exposure to micro- and nanoplastics and their associated risks.

“Congress lacks a clear assessment of what the EPA has accomplished in its work on microplastics and what work remains necessary to support reliable monitoring, risk assessment and potential regulatory action,” the letter, dated September 28, 2026, states.

The letter cites EPA plans to evaluate and address microplastic pollution, including EPA’s Safe and Sustainable Water Resources (SSWR) Strategic Research Action Plan for fiscal years 2023-2026 and its 2024 National Strategy to Prevent Plastic Pollution. According to the letter, those initiatives outlined plans to assess the effects of microplastics on human health and aquatic life, develop government-wide definitions, and standardize methods for quantifying microplastics. However, the lawmakers note uncertainty over the extent to which EPA has achieved these objectives.

The letter also challenges EPA’s exclusion of microplastics from the proposed UCMR 6, which the Agency justified by the lack of a validated analytical method for quantifying microplastics. The lawmakers note that EPA reported two years ago that it was in the early stages of developing such a method.

“Notably, the EPA has not scientifically justified, or even stated, that microplastics are less of a public health threat than any of the 30 other contaminants they included on the draft UCMR,” which is required by law, it adds.

The letter is led by Reps. Janelle Bynum (D-OR), Raja Krishnamoorthi (D-IL), and Watson Coleman (D-NJ). Sen. Merkley (D-OR) is the only senator among the signatories.

Questions for GAO

The letter outlines three questions for GAO to investigate.

First, it asks what microplastic- and nanoplastic-related activities the EPA has undertaken since fiscal year 2023. The request covers research, analytical method development, monitoring, risk assessment, pollution prevention, development and evaluation of capture and removal technologies, grant programs, and regulatory and other policy activities.

Second, it asks the extent to which EPA implemented the microplastics-related goals, outputs, and actions identified in the SSWR plan and 2024 National Strategy to Prevent Plastic Pollution. Specifically, the letter asks GAO to examine:

  • EPA’s progress towards developing government-wide definitions and validated, fit-for-purpose methods for collecting, extracting, identifying, quantifying, and characterizing microplastics and nanoplastics;
  • Research conducted or supported by EPA on the prevalence, sources, pathways, fate, and concentrations of microplastics and nanoplastics, and resulting findings;
  • EPA research on the toxicity of micro- and nanoplastics in human and aquatic life and resulting findings;
  • Methods, models, and tools developed or investigated by EPA to evaluate the effects of microplastics and nanoplastics on human health and aquatic resources and resulting findings;
  • EPA’s progress in developing testing, demonstrating, deploying, or funding management practices and technologies to prevent, capture, or remove microplastics and nanoplastics from the environment. This includes interventions to support these technologies and evaluations on the use of relevant water programs to address plastic pollution in waterways and oceans;
  • EPA’s implementation of policy and program opportunities identified in the national strategy, including evaluating the use of Clean Water Act (CWA) authorities and providing technical assistance to incorporate plastic pollution prevention, capture, and removal measures into relevant management plans.

Third, it asks what statutory, financial, workforce, technological, or infrastructure constraints affect EPA’s ability to advance its work of researching and regulating microplastics.

More information on EPA’s microplastics research can be found on EPA’s website.

Philip A. Moffat Quoted in Chemical Watch Article on Microplastics Regulation

On October 15, 2026, Verdant Law attorney Philip A. Moffat was quoted in a Chemical Watch article titled “Microplastics Draw Increasing Scrutiny from US State Lawmakers and Regulators.”

The article examines recent state-level efforts to address microplastics in products, including legislation introduced in New Jersey and California’s listing of microplastics as a candidate chemical. Mr. Moffat discussed the implications of these developments and the potential for other states to adopt microplastics regulations.

He also addressed the challenges of regulating microplastics, including defining the term and addressing secondary microplastics—particles generated unintentionally through product use, wear, and degradation.

A PDF of the article is available here.

NMED Seeks Public Input on New Mexico’s PFAS Exemptions

On October 8, 2026, the New Mexico Environment Department (NMED) held an in-person meeting to discuss whether certain products and materials should continue to be exempted from the state’s Per- and Poly-Fluoroalkyl Substances Protection Act.

The meeting follows the February 2026 passage of HJM 3, which directs NMED to report to the legislature “on the public health, environmental and economic risks of the exemptions codified in the” Act. The report must include recommendations on “whether such exemptions, such as the exemption for fluoropolymers, should be continued, modified or removed.”

HJM 3 characterizes the exemptions as “based on limited scientific literature regarding chemical degradation, environmental mobility and persistence, potential human exposure pathways and possible health impacts.”

The memorial also separately directs the New Mexico Environmental Improvement Board (EIB) to report on the Act’s implementation.

According to the meeting slides, NMED plans to present its interim findings to the Radioactive and Hazardous Materials Interim Committee on November 5, 2026. NMED is accepting public comments on the exemptions through December 31, 2026. The report to the legislature is due August 1, 2027.

NMED also held a webinar on HJM 3 on August 18, 2026.

Legal Background

Enacted in 2025, the Per- and Poly-Fluoroalkyl Substances Protection Act imposes phased prohibitions on products containing intentionally added PFAS. The Act also requires manufacturers to report products containing intentionally added PFAS to NMED by January 1, 2027. However, sixteen categories of products and materials—including fluoropolymers, used products, medical devices, semiconductors, certain refrigerants, and motor vehicles—are exempt from these requirements.

Earlier this year, EIB adopted regulations proposed by NMED to implement the statute. The regulations also establish a near-universal PFAS labeling requirement for consumer products, effective January 1, 2027. The labeling requirement applies even to products covered by the statute’s exemptions, subject to limited exceptions for used products, pesticides, veterinary products, medical devices, and drugs.

The District of New Mexico has since preliminarily blocked the labeling mandate on First Amendment grounds. A separate state-court challenge to the rule is also ongoing.

Focus on the Fluoropolymer Exemption

Much of the discussion surrounding the statutory exemptions has focused on fluoropolymers, a subclass of PFAS consisting of substances with polymeric per- or polyfluorinated carbon backbones. One of the best-known fluoropolymers is polytetrafluoroethylene (PTFE), also known by the brand name Teflon. PTFE is used in nonstick cookware, electronics, industrial equipment, medical devices, and numerous other applications.

The statutory exemption for fluoropolymers also encompasses a separate but related PFAS subclass known as polymeric perfluoropolyethers.

Fluoropolymers are the only exemption specifically identified in HJM 3. The memorial directs NMED to consider whether the exemptions, “such as the exemption for fluoropolymers,” should be modified. It also states that “additional health and environmental studies are needed to understand more fully the toxicological profiles, exposure risks and public health implications of fluoropolymers.”

Several plaintiffs in the federal litigation challenging the regulations implementing the Act have submitted comments urging NMED to recommend continuing the fluoropolymer exemption. They argue that fluoropolymers do not present health or environmental risks, serve critical or irreplaceable functions, and have been treated separately from other PFAS in other jurisdictions.

For more on New Mexico’s regulation of PFAS in products, visit our NM PFAS archive.